Predictors of undetectable hepatitis delta virus RNA at 48 weeks after end of treatment with bulevirtide monotherapy in the MYR301 study

Q: What type of study is this?

This is a Phase 2 study (also classified as: Human Clinical Trial).

Soo Aleman; Maurizia Brunetto; Antje Blank; Pietro Andreoné; Pavel Bogomolov; Vladimir Chulanov; Nina Mamonova; N Geyvandova; Vitaly Morozov; Olga Sagalova; T. E. Stepanova; Katja Deterding; Andrew H. Lichtman; Renée-Claude Mercier; D Manuilov; Sarah Arterburn; Julian Schulze zur Wiesch; Markus Cornberg; Stefan Zeuzem; Pietro Lampertico; H. Wedemeyer

doi:10.1055/s-0045-1810986

Key Points

Undetectable hepatitis delta virus RNA was maintained in a subset of patients after 48 weeks.
The analysis focuses on predictors based on data from a Phase 3 clinical trial with bulevirtide.
Patients who achieved undetectable HDV RNA at end of treatment were the primary focus of the evaluation.
Findings from this study support the potential long-term effects of bulevirtide in chronic hepatitis delta treatment.

Ask about this paper

Answers are grounded in this paper and cite their sources.

Implication

Phase 3 trial shows maintenance of undetectable HDV RNA in chronic hepatitis delta patients after 48 weeks, suggesting bulevirtide's effectiveness.

Abstract

Introduction: In MYR301, a Phase 3 study evaluating bulevirtide (BLV) monotherapy for treatment of chronic hepatitis delta (CHD) for 2–3 years, a subset of patients who achieved undetectable hepatitis delta virus (HDV) RNA by end of treatment (EOT) maintained undetectable viraemia at 48 weeks (W) of follow-up after EOT (FU48).

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Aleman et al. (2025) studied this question.

synapsesocial.com/papers/68c195559b7b07f3a0618e6c https://doi.org/10.1055/s-0045-1810986

View at Publisher

Ask AI

Bookmark

Share

Predictors of undetectable hepatitis delta virus RNA at 48 weeks after end of treatment with bulevirtide monotherapy in the MYR301 study

Key Points

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Predictors of undetectable hepatitis delta virus RNA at 48 weeks after end of treatment with bulevirtide monotherapy in the MYR301 study

Key Points

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading